Fig. 6

Morgana-NF-κB axis in breast cancer cells induces neutrophil recruitment in primary tumor. a Tumor weight 30 days after subcutaneous injection of 4T1 cells EMPTY or shMORG1 and shMORG2 infected or not with IκBα shRNA (n = 3 BALB/c mice per group). b Percentage of immune cells (gated on CD45⁺ cells) detected in the primary tumor 30 days after injection of 4T1 described in a (n = 3 BALB/c mice per group). c Percentage of neutrophils detected in the primary tumor of each mouse 30 days after injection of 4T1 cells described in a. d Immunoblotting of Morgana, IκBα and Vinculin in 4T1 cells described in a. e Luciferase assays of NF-κB activity in 4T1 cells described in a transfected with a NF-κB luciferase reporter or control vector. f Tumor weight 10 days after subcutaneous injection of 4T1 cells EMPTY or shMORG1 and shMORG2 (n = 3 BALB/c mice per group). g Percentage of immune system cells (gated on CD45⁺ cells) detected in the primary tumor 10 days after injection of 4T1 EMPTY or shMORG1 and shMORG2 (n = 3 BALB/c mice per group). h Percentage of neutrophils detected in the primary tumor of each mouse 10 days after injection of 4T1. Bars in graphs represent standard errors (*p < 0.05; **p < 0.01; ***p < 0.001)